美国癌症研究协会（AACR）年会是癌症领域的重点会议之一，第115届AACR年会将于当地时间2024年4月5日至10日在美国圣地亚哥举行。近日大会召开在即，本期小编汇总泌尿肿瘤领域中重磅的【临床试验（Clinical Trials，CT）】和【突破性研究（Late-Breaking，LB）】，以飨读者。
前列腺癌
摘要号CT023-Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot
用肿瘤内病毒模拟物poly-ICLC原位自体接种前列腺癌：使冷肿瘤变热
讲者：Sujit Nair
摘要号CT026-Systemic responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patientswith metastatic castrate-resistant prostate cancer (mCRPC)
SYNC-T疗法的全身反应：在mCRPC患者中使用肿瘤内多靶点免疫治疗进行原位个性化癌症疫苗接种
讲者：Charles Link
摘要号CT087-A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)
Gedatolisib与达罗他胺联合治疗mCRPC的1/2期、开放标签、随机、剂量寻找和剂量扩展研究
讲者：Igor Gorbatchevsky
摘要号CT108-Phase I data from TENDU101, a first-in-human trial of a novel synthetic peptide conjugate cancer vaccine platform assessed in recurrent prostate cancer patients before salvage treatment
TENDU101的I期数据，这是一项首创的合成肽偶联癌症疫苗平台的首次人体试验，评估在接受挽救治疗前的复发性前列腺癌患者
讲者：Sara Mangsbo
摘要号CT137-Efficacy and immunological outcomes of non-fucosylated anti-CTLA-4 (BMS-986218) + degarelix acetate vs. degarelix acetate alone in men with high-risk localized prostate cancer (Neo-Red-P)
非岩藻糖基化抗CTLA-4（BMS-986218）+地加瑞克与单独使用地加瑞克在高风险局部前列腺癌中的疗效和免疫学结果（Neo-Red-P）
讲者：Patrick McCann
摘要号CT138-Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort
评估纳武利尤单抗加伊匹木单抗在mCRPC患者中的临床和转化结果：AMADEUS前列腺扩展队列
讲者：Apostolia Tsimberidou
摘要号CT222-Efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC)
在ATM改变的晚期实体瘤（ASTs）或mCRPC患者中，ceralasertib在PLANETTE研究中的疗效和安全性
讲者：Rahul Aggarwal
摘要号CT224-Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
TATCIST试验的初步疗效和安全性结果：使用FPI-2265（225Ac-PSMA-I&T）进行PSMA指导的靶向α疗法治疗mCRPC
讲者：Luke Nordquist
摘要号CT231-Identification of a novel agnostic predictive multiomic signature via Elastic Net/Machine Learning in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
在TALAPRO-2中通过弹性网络/机器学习识别新型不可知预测性多组学特征，这是一项mCRPC患者中比较他拉唑帕尼+ 恩扎卢胺（ENZA）与安慰剂+ ENZA作为一线治疗的III期研究
讲者：Glenn Liu
摘要号LB110-Impact of circulating tumor cell-expressed prostate-specific membrane antigen and prostate-specific antigen transcripts in various stages of prostate cancer
循环肿瘤细胞表达的前列腺特异性膜抗原和前列腺特异性抗原转录本在前列腺癌不同阶段的影响
讲者：Jae-Seung Chung
摘要号LB161-Discovery of an oral, potent, and selective CDK9 molecular glue degrader SLX-3065 active in aggressive variant prostate cancers (AVPC)
发现一种口服、强效、选择性的CDK9分子胶水降解剂SLX-3065，对侵袭性变异前列腺癌有效
讲者：Chenyu Lin
摘要号LB177-Discovery of HC-4955, a novel AR-V7-targeting PROTAC for the treatment of mCRPC
发现HC-4955，一种新型AR-V7靶向PROTAC，可用于治疗mCRPC
讲者：Jing Li
摘要号LB217-Novel organoid models of lineage plasticity in castration resistant prostate cancer
CRPC谱系可塑性的新型类器官模型
讲者：Jinqiu Lu
摘要号LB259-Cell context-dependent role of KDM5D in ATR and CHK1 inhibitor sensitivity in prostate cancer
KDM5D在前列腺癌ATR和CHK1抑制剂敏感性中的细胞环境依赖性作用
讲者：Wenxiao Zheng
摘要号LB319-Klf5 acetylation remodels tumor microenvironment to constrain PTEN-deficient prostate tumor growth
Klf5乙酰化重塑肿瘤微环境以限制PTEN缺陷的前列腺肿瘤生长雄激素受体阳性前列腺癌对I类肌球蛋白依赖性的研究
讲者：Baotong Zhang
摘要号LB324-STING protein expression is increased in intermediate luminal cells in proliferative inflammatory atrophy of the prostate (PIA) and is absent in the majority of primary prostatic adenocarcinomas
STING蛋白表达在前列腺增生性炎性萎缩（PIA）的中间腔细胞中增加，在大多数原发性前列腺癌中不存在
讲者：Thomas Steele
摘要号LB390-Enhancing prostate cancer diagnosis: A deep learning approach for DNA ploidy prediction from whole slide images
提高前列腺癌诊断：一种深度学习方法，用于从全切片图像预测DNA倍性
讲者：Josselyn Sofia Vergara Cobos
摘要号LB411-Investigating the dependency of androgen receptor-positive prostate cancer on class I myosins
研究雄激素受体阳性前列腺癌对I类肌球蛋白的依赖性
讲者：Anoushka Kadam
膀胱癌/尿路上皮癌
摘要号CT084-A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
LY 4101174（ETx-22）（一种靶向nectin-4的ADC药物）在晚期或转移性尿路上皮癌和其他实体瘤中的I期研究（进行中）
讲者：Jonathan Rosenberg
摘要号CT085-Targeting androgen signaling in urothelial carcinoma
尿路上皮癌中靶向雄激素信号通路的研究
讲者：SHELDON HOLDER
摘要号CT086-Phase I study of intravesical Fc-optimized anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy
膀胱内Fc优化的抗CD 40激动剂抗体2141-V11治疗对卡介苗治疗无反应的NMIBC的I期研究
讲者：Juan Osorio
摘要号LB091-A-multigene signature for immunotherapy in patients with high risk non-muscle-invasive bladder cancer
一种用于高危非肌层浸润性膀胱癌患者免疫治疗的多基因标签
讲者：Seung-Woo Baek
摘要号LB105-Sensitive urothelial cancer detection via high volume urine DNA analysis
通过高容量尿DNA分析进行尿路上皮癌的灵敏检测
讲者：Jussi Nikkola
摘要号LB113-Immunogenicity of Atezolizumab plus personalized neoantigen vaccination (PGV-001) in patients with urothelial cancer in adjuvant vs metastatic setting
阿替利珠单抗联合个性化新抗原疫苗接种（PGV-001）在尿路上皮癌患者中的免疫原性（辅助vs转移性）
讲者： Nina Bhardwaj
摘要号LB256-New mechanistic insights into cisplatin resistance in muscle-invasive bladder cancer
肌层浸润性膀胱癌顺铂耐药机制的新认识
讲者： LILY ELIZABETH Feldman
摘要号LB327-DNA methylation biomarkers for early bladder cancer detection and treatment response monitoring
用于早期膀胱癌检测和治疗反应监测的DNA甲基化生物标志物
讲者： Paolo Piatti
摘要号LB437-Development of a bladder cancer-on-a-chip assay to assess the invasive potential of bladder cancer cells
膀胱癌细胞侵袭潜能芯片检测方法的建立
讲者： Ruth Vinall
摘要号LB448-VBC103: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond
VBC103：一种创新的Trop 2/Nectin 4靶向双特异性ADC，用于膀胱尿路上皮癌、三阴性乳腺癌等
讲者： Lingyu Guan
肾癌
摘要号CT002-CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study
晚期透明细胞肾细胞癌患者中的CTX 130同种异体CRISPR-Cas9工程嵌合抗原受体（CAR）T细胞：来自I期COBALT-RCC研究的长期随访和转化数据
讲者：Sumanta Pal
摘要号LB257-Possible involvement of PDL1 intrinsic signaling to acquired resistance to immunotherapy for renal cell carcinoma (RCC)
PDL1内在信号通路可能参与肾细胞癌免疫治疗获得性耐药
讲者：Jin-Sung Chung
https://www.aacr.org/meeting/aacr-annual-meeting-2024/abstracts/
排版编辑：肿瘤资讯-CY
苏公网安备32059002004080号
